Rhythm BiosciencesFRA:0RY +5.50%31 Pretax Margin % is -4,926.92% as of Dec. 2025. GuruFocus rates FRA:0RY with a GF Score™ of 31/100. The stock has 5 warning signs investors should review. Among 202 Medical Diagnostics & Research companies, Rhythm Biosciences ranks worse than 98.02% on this metric.
The historical rank and industry rank for Rhythm Biosciences's Pretax Margin % or its related term are showing as below:
FRA:0RY'
s Pretax Margin % Range Over the Past 10 Years
Min: -15316 Med: -15316 Max: -14513.04
Current: -14513.04
FRA:0RY's Pretax Margin % is ranked worse than 98.02% of 202
companies
in the Medical Diagnostics & Research industry
Industry Median: -3.565
vs FRA:0RY: -14513.04
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Rhythm Biosciences Pretax Margin % Related Terms
Rhythm Biosciences Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Rhythm Biosciences's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:0RY vs TMO, DHR, IDXX: Pretax Margin % Comparison
For the Diagnostics & Research subindustry, Rhythm Biosciences's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rhythm Biosciences Pretax Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Rhythm Biosciences's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Rhythm Biosciences's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rhythm Biosciences (FRA:0RY) has a Pretax Margin % of -4,926.92% as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Rhythm Biosciences and its competitors. According to the industry distribution chart, Rhythm Biosciences ranks #198 out of 202 companies in the Medical Diagnostics & Research industry, placing it in the top 98%.
Is Rhythm Biosciences' Pretax Margin % too high?
Rhythm Biosciences' current Pretax Margin % is -4,926.92%. Based on the distribution chart, Rhythm Biosciences ranks #198 out of 202 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Rhythm Biosciences has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Rhythm Biosciences' Pretax Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Rhythm Biosciences ranks #198 out of 202 companies for Pretax Margin %. This places Rhythm Biosciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Medical Diagnostics & Research company?
A good Pretax Margin % depends on the Medical Diagnostics & Research industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Rhythm Biosciences and its competitors. Rhythm Biosciences's current Pretax Margin % is -4,926.92%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rhythm Biosciences stock overvalued right now?
Rhythm Biosciences (FRA:0RY) has a current Pretax Margin % of -4,926.92%. The current Pretax Margin % is -4,926.92%. Rhythm Biosciences' overall GF Score™ is 31/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Rhythm Biosciences (FRA:0RY), the current Pretax Margin % is -4,926.92% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Rhythm Biosciences Ltd is a medical diagnostics technology company. It is engaged in developing and commercializing Australian medical diagnostics technology for sale to national and international markets. The product includes ColoSTAT a proposed diagnostic blood test for screening for colorectal cancer. The company operates predominantly in one business and geographical segment which is the research and development of biosciences in Australia.
31GF Score
Get the complete analysis for FRA:0RY
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:0RY has been successfully added to your 
